YANO Takamitsu

J-GLOBAL         Last updated: Dec 7, 2019 at 17:32
 
Avatar
Name
YANO Takamitsu
URL
https://triplexbio.tech/
Affiliation
Triplex Therapeutics Inc.
Section
Headquarters, the laboratory
Job title
CEO and Representative Director
Degree
Doctor of Philosophy (PhD)(The University of Tokyo), Master of Medical Science (MMS)(University of Tsukuba), Bachelor of Science (BS)(Yamagata University)
Other affiliation
University of California, Santa Barbara

Profile

Dr. Takamitsu Yano is a founder, CEO and a scientist of a biopharmaceutical company that specializes in the research and development of innovative gene drugs to treat rare neuromuscular diseases.

Beginning with his research on the control mechanism of replication of mutant mitochondrial DNA in human cells in his doctoral program at the University of Tokyo, he developed "ML1 polyamide", a therapeutic substance which has a unique mechanism of pharmacological action for mitochondrial disease, MELAS (Mitochondrial myopathy, Encephalopathy, Lactic acidosis, and Stroke-like episodes), through his own study.

Taking advantage of the establishment of this domestic patent, he launched Triplex Therapeutics, a biotechnology company from the University of Tokyo, working as its founder and CEO, he still stands himself in the laboratory as a researcher and directs research and development of innovative gene medicine for treating rare neuromuscular diseases.

Aiming to develop new drugs with a fundamental therapeutic effect on mitochondrial diseases, the patent for substance and pharmaceutical composition of ML1 polyamide has already been acquired in Japan, the United States, and six European countries.

Currently, Triplex Therapeutics is preparing for in-vivo level tests towards clinical trials of MELAS, a type of lethal mitochondrial disease, and new R & D program for an entirely new genetic drug that has never existed before overcoming the conventional drugs of "exon skipping" is ongoing for neuromuscular diseases such as Duchenne Muscular Dystrophy (DMD) caused by mutations in dystrophin gene.

These genetic diseases are the most frequent and fatal diseases of humanity, and we are continuing our earnest research for a complete recovery and total patients' reintegration to our society beyond the mere “life support” that was the limit of usual medicines.

Research Areas

 
 

Academic & Professional Experience

 
Nov 2016
 - 
Today
CEO, Triplex Therapeutics Inc.
 
Nov 2015
 - 
Mar 2016
Researcher, School of Medicine, University of Tsukuba
 
Feb 2014
 - 
Jan 2016
External Cooperative Researcher, University Hospital, Ibaraki Prefectural University of Health Science
 
Jul 2012
 - 
Jun 2013
Visiting Scholar, Department of Neuroscience, School of Medicine, University of California, San Diego
 
Apr 2012
 - 
Mar 2013
Assistant Professor, Center for Integrated Medical Science, School of Medicine, Keio University
 
Apr 2011
 - 
Mar 2012
Research Assistant, Disease Research Section II, National Center for Neurology and Psychiatry
 

Education

 
 
   
 
Molecular Medical Science, Department of Medical Genome Sciences, The University of Tokyo, Graduate School of Frontier Sciences (GSFS)
 
 
   
 
Medical Genetics, Graduate School of Medical Sciences, University of Tsukuba
 
 
   
 
Department of Biochemistry and Molecular Biology, College of Letters and Science, University of California, Santa Barbara
 
 
   
 
Molecular Genetics, Department of Biological Science, Faculty of Science, Yamagata University
 

Awards & Honors

 
Nov 2019
Chiba City Industrial Promotion Foundation Venture Cup Chiba Business Plan Competition, Award of Excellence
 
Jan 2018
Chiba Prefecture Business Model Competition 2017, Incentive Award
 
Jun 2013
2013 Burroughs Wellcome Scholarship Award, Burroughs Wellcome Fund
 
Sep 2011
Young Investigator Award, The Japanese Society of Mitochondrial Research and Medicine, Asian Society for Mitochondrial Research and Medicine
 
Jun 2011
Burroughs Wellcome Awards for New Investigators, Burroughs Wellcome Fund
 

Published Papers

 
Pyrrole-imidazole polyamide, a synthetic DNA-binding compound, is effective at increasing levels of wild-type mtDNA in both cybrid cells and MELAS patient-derived fibroblast cells with the MELAS A3243G mutation by a selective promotion of wild-type...
Yano T, Takeuchi-Tomita N, Ueda T, Haas RH.
MITOCHONDRION   13(6) 924   Nov 2013   [Refereed]
YANO Takamitsu
International Journal of Molecular Medicine   25(1) 153-158   Jan 2010   [Refereed]

Conference Activities & Talks

 
The novel therapeutic strategy for mitochondrial DNA disease: A selective promotion of wild-type mitochondrial DNA replication by a synthetic DNA-binding compound
YANO Takamitsu
Dec 2011   
Successful preferential propagation of wild‐type mitochondrial DNA in human cells harboring the mt tRNALeu(UUR) A3243G mutation by a synthetic DNA‐binding compound [Invited]
YANO Takamitsu
United Mitochondrial Disease Foundation, Mitochondrial Medicine 2011: Chicago   Jun 2011   
Normal fibroblast nuclear transfer causes selective loss of mutant mitochondrial DNA harboring the A3243G mutation in human cybrid cells
YANO Takamitsu
The 7th Annual Conference of the Japanese Society of Mitochondrial Research and Medicine (J-mit)   Dec 2007   
Preferential loss of mitochondrial DNA harboring the pathogenic mutation tRNALeu(UUR) 3243 A->G in human somatic cell hybrids
YANO Takamitsu
The 5th Annual Conference of the Japanese Society of Mitochondrial Research and Medicine (J-mit)   Dec 2005   

Research Grants & Projects

 
Development of novel therapeutic molecules for Duchenne Muscular Dystrophy
Investigator(s): YANO Takamitsu
Translational research of therapeutic mitochondrial DNA-binding compounds (ML1 polyamide) for mitochondrial diseases
Investigator(s): YANO Takamitsu